Please login to the form below
Data by
12
Revenue 2014Amgen
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Amgen's 2013 sales performance.
Biocon backs away from biosimilar filings in Europe
In a statement, the company said it had been forced to withdraw its regulatory filings for biosimilar versions of Roche's breast cancer drug Herceptin (trastuzumab) and Amgen's long-acting ... Sales of Herceptin were around $7bn last year, while Amgen
Samsung deal with Takeda looks beyond biosimilars
Samsung Bioepis has already been granted approvals for biosimilars of Amgen's Enbrel (etanercept), Johnson &Johnson's Remicade (infliximab) and Sanofi's Lantus (insulin glargine), and has filed for versions of
SMC gives green light for Amgen’s Kyprolis
SMC gives green light for Amgen’ s Kyprolis. The committee also gives verdict on three other products. ... Multiple myeloma patients - who have received at least one prior therapy - in Scotland will soon be able to access Amgen’s Kyprolis (carfilzomib
SMC gives green light for Amgen’s Kyprolis
SMC gives green light for Amgen’ s Kyprolis. The committee also gives verdict on three other products. ... Multiple myeloma patients - who have received at least one prior therapy - in Scotland will soon be able to access Amgen’s Kyprolis (carfilzomib
Audit exposes gaps in pharma's promises on trial transparency
transparency, followed by LEO Pharma, Takeda, Pfizer, Novartis, Novo Nordisk, Boehringer Ingelheim, Amgen, Merck &Co and AbbVie.
| Global revenue 2014 |
|---|
| 1: Novartis |
| 2: Pfizer |
| 3: Roche |
| 4: Sanofi |
| 5: Merck & Co. |
| 6: Johnson & Johnson |
| 7: GlaxoSmithKline |
| 8: AstraZeneca |
| 9: Gilead Sciences |
| 10: Takeda |
| 11: AbbVie |
| 12: Amgen |
| 13: Teva |
| 14: Lilly |
| 15: Bristol-Myers Squibb |
| 16: Bayer |
| 17: Novo Nordisk |
| 18: Astellas |
| 19: Boehringer Ingelheim |
| 20: Actavis |
| 21: Otsuka |
| 22: Daiichi Sankyo |
| 23: Biogen Idec |
| 24: Baxter |
| 25: Merck KGaA |
| US revenue 2014 |
|---|
| 1: Gilead Sciences |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Roche |
| 5: Novartis |
| 6: Amgen |
| 7: Merck & Co. |
| 8: Sanofi |
| 9: AbbVie |
| 10: Actavis |
| 11: AstraZeneca |
| 12: GlaxoSmithKline |
| 13: Lilly |
| 14: Bristol-Myers Squibb |
| 15: Novo Nordisk |
| Oncology revenue 2014 |
|---|
| 1: Roche |
| 2: Novartis |
| 3: Celgene |
| 4: Johnson & Johnson |
| 5: Bristol-Myers Squibb |
| 6: Lilly |
| 7: Takeda |
| 8: AstraZeneca |
| 9: Merck & Co. |
| 10: Amgen |
| 11: Pfizer |
| 12: Astellas |
| 13: Bayer |
| 14: Otsuka |
| 15: Sanofi |
| 16: Merck KGaA |
| 17: Eisai |
| 18: AbbVie |
| 19: Pharmacyclics |
| 20: Incyte |
| Immunology revenue 2014 |
|---|
| 1: AbbVie |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Amgen |
| 5: Merck & Co. |
| 6: Astellas |
| 7: Roche |
| 8: Novartis |
| 9: Bristol-Myers Squibb |
| 10: Mitsubishi Tanabe |
| 11: UCB |
| 12: Hisamitsu |
| 13: Daiichi Sankyo |
| 14: Takeda |
| Metabolic revenue 2014 |
|---|
| 1: Novo Nordisk |
| 2: Sanofi |
| 3: Merck & Co. |
| 4: Lilly |
| 5: AstraZeneca |
| 6: Takeda |
| 7: Novartis |
| 8: Amgen |
| 9: Bayer |
| 10: Merck KGaA |
| 11: Salix Pharmaceuticals |
| 12: AbbVie |
| 13: Dainippon Sumitomo Pharma |
| 14: Kyowa Hakko Kirin |
| 15: Mitsubishi Tanabe |
| Biologic revenue 2014 |
|---|
| 1: Roche |
| 2: Amgen |
| 3: Novo Nordisk |
| 4: AbbVie |
| 5: Sanofi |
| 6: Johnson & Johnson |
| 7: Pfizer |
| 8: Merck & Co. |
| 9: Lilly |
| 10: Biogen Idec |
| 11: Merck KGaA |
| 12: GlaxoSmithKline |
| 13: Bristol-Myers Squibb |
| 14: Novartis |
| 15: Bayer |
Data by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
Featured jobs
- Director of Scientific and Editorial Services
-
Great salary and benefits - Circa 100K
- Account Manager – Healthcare Advertising
-
Salary TBC
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- JAM – Med Comms – Independent Agency
-
Salary TBC
-
Principal Medical Writer
-
Great salary and benefits
- Head of Communications - Based Cambridge
-
Excellent Basic and Flex Benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Principal Medical Writer, Medical Education Agency
-
£46, 000 – £56, 000 benefits
- Account Executive - Pharma and Life Sciences Brighton or Maccles...
-
Competitive Salary
- Senior Account Manager/ Account Director – Pharma and Life Scien...
-
Competitive Salary
- Freelance Medical Copywriter, Healthcare Advertising Agency
-
according to skills and experience
-
Editorial Director - BioScience
-
Competitive Salary
-
Brand Manager
-
Competitive salary and package
- Account Manager, Medical Communications
-
£30, 000-£40, 000
Subscribe to our email news alerts
- Novartis trial marks ResearchKit first in MS
- Samsung deal with Takeda looks beyond biosimilars
- Ocrevus off to a flying start as Roche raises 2017 forecasts
- NICE set to reject Pfizer's leukaemia drug Besponsa
- Biocon backs away from biosimilar filings in Europe
- Astellas extends phase III programme for Rydapt rival gilteritinib
- Hugh Cole joins Jounce Therapeutics as chief business officer
- PharmaLex appoints Dr Adam King to its regulatory team
- The Pharma Wars Series
- Ironwood claims FDA OK for former AZ gout drug
- Astellas extends phase III programme for Rydapt rival gilteritinib
- What pharma marketers can learn from growth hacking?
PMHub
GEM Marketing Ltd
GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....
Latest intelligence
- The Pharma Wars Series
- The future galaxy is complex. Where markets are more competitive and customers more segmented, you’ve got to be smarter. But not only smarter, the Jedi today needs to be everywhere...
- What pharma marketers can learn from growth hacking?
- Growth hackers instinctively blend technical skills with creative thinking...
- The sound of silence puts the squeeze on generics and biosimilars
- Medicines for Europe vows to get governments talking to realise potential...
Quick links
Infographics
